ABS (Australia Bureau of Statistics) (1995). Deaths, Australia 1994. ABS Catalogue No. 3302.0. AGPS, Canberra, 1995.

Alcabes P, Munoz A, Vlahov D and Freidlan GH (1993). Incubation period of human immunodeficiency virus. Epidemiol Rev, 15: 303-318

Becker NG, Watson LF and Carlin JB (1991). A method of non-parametric back-projection and its application to AIDS data. Stat Med, 10: 1527-1542

Bennett WG, Inoue Y, Beck JR, et al (1997). Estimates of the cost-effectiveness of a single course of interferonalpha2B in patients with histologically mild chronic hepatitis C. Ann Intern Med, 127: 855-865.

Bonkovsky HL, Woolley JM and the Consensus Interferon Study Group (1999). Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology, 29: 264-270.

Bruneau J, Lamothe F, Franco E, et al (1997). High rates of HIV infection among injecting drug users participating in needle exchange programs in Montreal: results of a cohort study. Am J Epidemiol, 145: 994-1002.

Des Jarlais DC, Hagan H, Friedman S, et al (1995). Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA, 274: 1226-1231.

Drucker E, Lurie P, Wodak A and Alcabes P (1998). Measuring harm reduction: the effects of needle and syringe exchange programs and methadone maintenance on the ecology of HIV. AIDS, 12 (Suppl A): S217-S230.

Drummond et al (1997). Methods for the Economic Evaluation of Health Care Programmes; 2nd edition, Oxford University Press

English D, Holman CDJ, Milne E, et al (1995). The quantification of drug caused morbidity and mortality in Australia, 1995 edition. Commonwealth Department of Human Services and Health, Canberra, 1995.

Fattovich G, Giustina G, Degos F, et al (1997). Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterol, 112: 463-472.

Freeman A, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd A, Marinos G and Kaldor JM (2001). Estimating progression to cirrhosis in chronic hepatitis C. Hepatology, 34: 809-816. Top of page

Grulich AE, Wan X, Law MG, Coates M and Kaldor JM (1999). Risk of cancer in people with AIDS. AIDS, 13: 839-843.

Guydish J, Bucardo J, Young M, Woods W, Grinstead O and Clark W (1993). Evaluating needle exchange: Are there negative effects? AIDS, 7: 871-876.

Hagan H, McGough JP, Thiede H, et al (1999). Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol, 149: 203-213.

Hall WD, Ross JE, Lynskey MT, Law MG and Degenhardt LJ (2000). How many dependent heroin users are there in Australia? Med J Aust, 173: 528-531.

Holtgrave DR and Pinkerton SD (1997). Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. JAIDS, 16: 54-62.

Hurley SF, Jolley DJ and Kaldor JM (1997). Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet, 349: 1797-1800.

Hurley SF, Kaldor JM, Carlin JB, et al (1995). The usage and costs of health services for HIV infection in Australia. AIDS, 9: 777-785.

Law MG on behalf of the Hepatitis C Virus Projections Working Group (1999). Modelling the hepatitis C virus epidemic in Australia. J Gastro Hepatol, 14:1100-1107.

MacDonald M, Crofts N and Kaldor J (1996). Transmission of hepatitis C: Rates, routes and cofactors. Epidemiol Rev, 18: 137-148.

Marschner IC and Watson LF (1992). An improved EMS algorithm for back-projection of AIDS incidence data. Research Report 92/1, Department of Statistics, La Trobe University, Melbourne.

NCHECR (2001). HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2001. National Centre in HIV Epidemiology and Clinical Research (Ed), Sydney, 2001.

Rodger AJ, Jolley D, Thompson SC, Lanigan A and Crofts N (1999). The impact of diagnosis of hepatitis C virus on quality of life. Hepatology, 30: 1299-1301.

Rosenberg PS, Gail MH and Carroll RJ (1992). Estimating HIV prevalence and projecting AIDS incidence in the United States: a model that accounts for therapy and changes in the surveillance definition of AIDS. Stat Med, 11: 1633-1655.

Schoenbaum EE, Hartel DM and Gourevitch MN (1996). Needle exchange use among a cohort of injecting drug users. AIDS, 10: 1729-1734.

Shiell A, Briggs A and Farrell G (1994). The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C. Med J Aust, 160: 268-272.

Tengs, Tammy O, Wallace, Amy, One Thousand Health-Related Quality-of-Life Estimates, Medical Care, 2000; Vol 38 No. 6: 583-637
Top of page
Thorley A (1981). Longitudinal studies of drug dependence. In: Drug problems in Britain: a review of ten years. Eds: Edwards G, Busch C. Academic Press.

US Census Bureau & UNAIDS (2000). HIV/AIDS Surveillance Data Base. Health Studies Branch, International Programs Center Population Division, US Census Bureau, Washington.

van Ameijden EJC, van den Hoek JAR and Coutinho RA (1994). Injecting risk behaviour among drug users in Amsterdam 1986 to 1992, and its relationship to AIDS prevention programs. Am J Pub Health, 84: 275.

Watters JK, Estilo MJ, Clark GL and Lorvick J (1994). Syringe and needle exchange as HIV/AIDS prevention for injecting drug users. Journal of American Medical Association, 271: 115-120.

Wolk J, Wodak A, Guinan JJ, Macaskill P and Simpson JM (1990). The effect of a needle and syringe exchange on a methadone maintenance unit. British Journal of Addiction, 85. 1445-1450.